This is an extraordinary paper.
https://www.nature.com/articles/s41597-022-01264-y
Congratulations to everyone involved. Not only is this an important study, but the way it was done, team science at its best with shared authorship, open data sharing to public data repositories, open code sharing in accordance with both the spirit of FAIR as well as the letter of FAIR principles.
Not all patients respond equally well to treatment. Here is the link to the clinical trajectories paper identifying three distinct trajectories for early seropositive rheumatoid arthritis patients.
RA-MAP Consortium, 2021. Characterization of disease course and remission in early seropositive rheumatoid arthritis: results from the TACERA longitudinal cohort study. Therapeutic advances in musculoskeletal disease, 13, p.1759720X211043977. https://doi.org/10.1177/1759720X211043977
